FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:447-452 August 14, 1997 Number 7 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Antithrombotic therapy with heparin plus aspirin reduces the rate of ischemic events in patients with unstable coronary artery disease. Low-molecular-weight heparin has a more predictable anticoagulant effect than standard unfractionated heparin, is easier to administer, and does not require monitoring.

Methods In a double-blind, placebo-controlled study, we randomly assigned 3171 patients with angina at rest or non–Q-wave myocardial infarction to receive either 1 mg of enoxaparin (low-molecular-weight heparin) per kilogram of body weight, administered subcutaneously twice daily, or continuous intravenous unfractionated heparin. Therapy was continued for a minimum of 48 hours to a maximum of 8 days, and we collected data on important coronary end points over a period of 30 days.

Results At 14 days the risk of death, myocardial infarction, or recurrent angina was significantly lower in the patients assigned to enoxaparin than in those assigned to unfractionated heparin (16.6 percent vs. 19.8 percent, P = 0.019). At 30 days, the risk of this composite end point remained significantly lower in the enoxaparin group (19.8 percent vs. 23.3 percent, P = 0.016). The need for revascularization procedures at 30 days was also significantly less frequent in the patients assigned to enoxaparin (27.0 percent vs. 32.2 percent, P = 0.001). The 30-day incidence of major bleeding complications was 6.5 percent in the enoxaparin group and 7.0 percent in the unfractionated-heparin group, but the incidence of bleeding overall was significantly higher in the enoxaparin group (18.4 percent vs. 14.2 percent, P = 0.001), primarily because of ecchymoses at injection sites.

Conclusions Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non–Q-wave myocardial infarction in the early phase. This benefit of enoxaparin was achieved with an increase in minor but not in major bleeding.

Source Information

From the Division of Cardiology, Allegheny University Hospitals–Hahnemann Division, Philadelphia (M.C.); Hôpital St. Sacrement, Quebec, Que., Canada (C.D.); Instituto de Cardiologia y Cirugia, Buenos Aires, Argentina (E.P.G.); McMaster University, Hamilton, Ont., Canada (A.G.G.T.); Rhône-Poulenc Rorer, Collegeville, Pa., and Paris (G.J.F., J.P., F.B.); St. Michael's Hospital, Toronto (S.G.); Duke University, Durham, N.C. (R.M.C.); and the Royal Infirmary, Edinburgh, United Kingdom (K.A.A.F.). Other authors were Jim Stephens, M.S., Rhône-Poulenc Rorer, Collegeville, Pa.; and Beth Weatherley, M.S., Duke University, Durham, N.C.

Address reprint requests to Dr. Cohen at the Division of Cardiology, MCP–Hahnemann School of Medicine, Allegheny University of the Health Sciences, Mail Stop-119, Philadelphia, PA 19102.

Full Text of this Article

Related Letters:

Low-Molecular-Weight Heparin versus Unfractionated Heparin for Unstable Coronary Disease
Kearon C., Baker B. A., Adelman M. D., Krulewitz A., Goodall A. H., Knight C., Cohen M., Armstrong P. W.
Extract | Full Text  
N Engl J Med 1998; 338:129-131, Jan 8, 1998. Correspondence

This article has been cited by other articles:

• Kumar, A., Cannon, C. P. (2009). Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc. 84: 917-938 [Abstract] [Full Text]  
• Viskov, C., Bouley, E., Hubert, P., Martinez, C., Herman, F., Jeske, W., Hoppensteadt, D., Walenga, J. M., Fareed, J. (2009). Isolation and Characterization of Contaminants in Recalled Unfractionated Heparin and Low-Molecular-Weight Heparin. CLIN APPL THROMB HEMOST 15: 395-401 [Abstract]  
• Nutescu, E. A, Spinler, S. A, Wittkowsky, A., Dager, W. E (2009). Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings. The Annals of Pharmacotherapy 43: 1064-1083 [Abstract] [Full Text]  
• Adiguzel, C., Jeske, W. P., Hoppensteadt, D., Walenga, J. M., Bansal, V., Fareed, J. (2009). Structural and Functional Characterization of Low-molecular-weight Heparins: Impact on the Development of Guidelines for Generic Products. CLIN APPL THROMB HEMOST 15: 137-144 [Abstract]  
• ALEXANDER, J. H. (2009). The current state of antiplatelet therapy in acute coronary syndromes: The data and the real world. Cleveland Clinic Journal of Medicine 76: S16-S23 [Abstract] [Full Text]  
• Maxwell, C. B, Holdford, D. A, Crouch, M. A, Patel, D. A (2009). Cost-Effectiveness Analysis of Anticoagulation Strategies in Non-ST-Elevation Acute Coronary Syndromes. The Annals of Pharmacotherapy 43: 586-595 [Abstract] [Full Text]  
• Lopes, R. D., Alexander, K. P., Manoukian, S. V., Bertrand, M. E., Feit, F., White, H. D., Pollack, C. V. Jr, Hoekstra, J., Gersh, B. J., Stone, G. W., Ohman, E. M. (2009). Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. J Am Coll Cardiol 53: 1021-1030 [Abstract] [Full Text]  
• Budaj, A., Eikelboom, J. W., Mehta, S. R., Afzal, R., Chrolavicius, S., Bassand, J.-P., Fox, K. A.A., Wallentin, L., Peters, R. J.G., Granger, C. B., Joyner, C. D., Yusuf, S., on behalf of OASIS 5 Investigators, (2009). Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30: 655-661 [Abstract] [Full Text]  
• Lopes, R. D., Alexander, K. P., Marcucci, G., White, H. D., Spinler, S., Col, J., Aylward, P. E., Califf, R. M., Mahaffey, K. W. (2008). Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. Eur Heart J 29: 1827-1833 [Abstract] [Full Text]  
• Dobesh, P. P., Phillips, K. W., Haines, S. T. (2008). Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. Am J Health Syst Pharm 65: S22-S28 [Abstract] [Full Text]  
• Harrington, R. A., Becker, R. C., Cannon, C. P., Gutterman, D., Lincoff, A. M., Popma, J. J., Steg, G., Guyatt, G. H., Goodman, S. G. (2008). Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 670S-707S [Abstract] [Full Text]  
• Mehta, S. R. (2008). Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes. Eur Heart J Suppl 10: C14-C21 [Abstract] [Full Text]  
• American College of Cardiology/American Heart Asso, , 2007 Writing Group to Review New Evidence and Upda, , King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O. (2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. J Am Coll Cardiol 51: 172-209 [Full Text]  
• King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, , Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Buller, C. E., Creager, M. A., Ettinger, S. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W. (2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117: 261-295 [Full Text]  
• Mousa, S. A., Zhang, F., Aljada, A., Chaturvedi, S., Takieddin, M., Zhang, H., Chi, L., Castelli, M. C., Friedman, K., Goldberg, M. M., Linhardt, R. J. (2007). Pharmacokinetics and Pharmacodynamics of Oral Heparin Solid Dosage Form in Healthy Human Subjects. J Clin Pharmacol 47: 1508-1520 [Abstract] [Full Text]  
• Murphy, S. A., Gibson, C. M., Morrow, D. A., Van de Werf, F., Menown, I. B., Goodman, S. G., Mahaffey, K. W., Cohen, M., McCabe, C. H., Antman, E. M., Braunwald, E. (2007). Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28: 2077-2086 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• LaPointe, N. M. A., Chen, A. Y., Alexander, K. P., Roe, M. T., Pollack, C. V. Jr, Lytle, B. L., Ohman, M. E., Gibler, B. W., Peterson, E. D. (2007). Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes. Arch Intern Med 167: 1539-1544 [Abstract] [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• De Caterina, R., Husted, S., Wallentin, L., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S. D., Montalescot, G., Siegbahn, A., Verheugt, F. W.A., Weitz, J. (2007). Anticoagulants in heart disease: current status and perspectives. Eur Heart J 0: ehl492v1-34 [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation 114: 2871-2891 [Full Text]  
• Peeters, M. J., Sydoruk, B. (2006). Fondaparinux in patients with ST-segment elevation myocardial infarction.. JAMA 296: 2088-2088 [Full Text]  
• Harding, S A, Din, J N, Sarma, J, Josephs, D H, Fox, K A A, Newby, D E (2006). Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart 92: 1635-1638 [Abstract] [Full Text]  
• Cohen, M., Mahaffey, K. W., Pieper, K., Pollack, C. V. Jr, Antman, E. M., Hoekstra, J., Goodman, S. G., Langer, A., Col, J. J., White, H. D., Califf, R. M., Ferguson, J. J., on behalf of the SYNERGY Trial Investigators, (2006). A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial: Enoxaparin Versus Unfractionated Heparin in Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol 48: 1346-1354 [Abstract] [Full Text]  
• Pleym, H., Videm, V., Wahba, A., Asberg, A., Amundsen, T., Bjella, L., Dale, O., Stenseth, R. (2006). Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.. Eur. J. Cardiothorac. Surg. 29: 933-940 [Abstract] [Full Text]  
• Ellis, M. H., Hadari, R., Tchuvrero, N., Shapira, S., Kovlenko, I., Kozmiakova, M., Zissin, R., Elis, A. (2006). Hemorrhagic Complications in Patients Treated with Anticoagulant Doses of a Low Molecular Weight Heparin (Enoxaparin) in Routine Hospital Practice. CLIN APPL THROMB HEMOST 12: 199-204 [Abstract]  
• Meurin, P., Tabet, J. Y., Weber, H., Renaud, N., Driss, A. B. (2006). Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement. Circulation 113: 564-569 [Abstract] [Full Text]  
• Alexander, K. P., Chen, A. Y., Roe, M. T., Newby, L. K., Gibson, C. M., Allen-LaPointe, N. M., Pollack, C., Gibler, W. B., Ohman, E. M., Peterson, E. D., for the CRUSADE Investigators, (2005). Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes. JAMA 294: 3108-3116 [Abstract] [Full Text]  
• (2005). Part 8: Stabilization of the Patient With Acute Coronary Syndromes. Circulation 112: IV-89-IV-110 [Full Text]  
• (2005). Part 5: Acute Coronary Syndromes. Circulation 112: III-55-III-72 [Full Text]  
• Hetzel, G. R., Sucker, C. (2005). The heparins: all a nephrologist should know. Nephrol Dial Transplant 20: 2036-2042 [Full Text]  
• Murphy, J. T., Fahy, B. G. (2005). Thrombosis of Sirolimus-Eluting Coronary Stent in the Postanesthesia Care Unit. Anesth. Analg. 101: 971-973 [Abstract] [Full Text]  
• Jones, H. U., Muhlestein, J. B., Jones, K. W., Renlund, D. G., Bair, T. L., Bunch, T. J., Horne, B. D., Lappe, D. L., Anderson, J. L., Doty, D. B. (2005). Early Postoperative Use of Unfractionated Heparin or Enoxaparin is Associated with Increased Surgical Re-Exploration for Bleeding. Ann. Thorac. Surg. 80: 518-522 [Abstract] [Full Text]  
• Bassand, J.-P., Priori, S., Tendera, M. (2005). Evidence-based vs. 'impressionist' medicine: how best to implement guidelines. Eur Heart J 26: 1155-1158 [Abstract] [Full Text]  
• Onorati, F., Feo, M. D., Mastroroberto, P., Virgilio, A. d., Esposito, A., Polistena, M., Renzulli, A., Cotrufo, M. (2005). Unstable angina and non-ST segment elevation: surgical revascularization with different strategies. Eur. J. Cardiothorac. Surg. 27: 1043-1050 [Abstract] [Full Text]  
• Spinler, S. A., Dobesh, P., Macie, C., Douketis, J. (2005). Dose Capping Enoxaparin Is Unjustified and Denies Patients With Acute Coronary Syndromes a Potentially Effective Treatment. Chest 127: 2288-2290 [Full Text]  
• Wells, P. S., Anderson, D. R., Rodger, M. A., Forgie, M. A., Florack, P., Touchie, D., Morrow, B., Gray, L., O'Rourke, K., Wells, G., Kovacs, J., Kovacs, M. J. (2005). A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Arch Intern Med 165: 733-738 [Abstract] [Full Text]  
• Authors/Task Force Members, , Silber, S., Albertsson, P., Aviles, F. F., Camici, P. G., Colombo, A., Hamm, C., Jorgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., Urban, P., Stone, G. W., Wijns, W. (2005). Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26: 804-847 [Full Text]  
• Kalus, J. S, Moser, L. R (2005). Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction. The Annals of Pharmacotherapy 39: 481-491 [Abstract] [Full Text]  
• Gluckman, T. J., Sachdev, M., Schulman, S. P., Blumenthal, R. S. (2005). A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes. JAMA 293: 349-357 [Abstract] [Full Text]  
• Pineo, G. F., Hull, R. D. (2005). Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly. CLIN APPL THROMB HEMOST 11: 15-23 [Abstract]  
• Spratt, J C, Camenzind, E (2004). Plaque stabilisation by systemic and local drug administration. Heart 90: 1392-1394 [Full Text]  
• Hanania, G, Cambou, J-P, Gueret, P, Vaur, L, Blanchard, D, Lablanche, J-M, Boutalbi, Y, Humbert, R, Clerson, P, Genes, N, Danchin, N, for the USIC 2000 Investigators, (2004). Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart 90: 1404-1410 [Abstract] [Full Text]  
• Moser, L. R, Kalus, J. S (2004). Role of Low-Molecular-Weight Heparin in Invasive Management of Non-ST-Elevation Acute Coronary Syndromes. The Annals of Pharmacotherapy 38: 2094-2104 [Abstract] [Full Text]  
• Bhatt, D. L., Roe, M. T., Peterson, E. D., Li, Y., Chen, A. Y., Harrington, R. A., Greenbaum, A. B., Berger, P. B., Cannon, C. P., Cohen, D. J., Gibson, C. M., Saucedo, J. F., Kleiman, N. S., Hochman, J. S., Boden, W. E., Brindis, R. G., Peacock, W. F., Smith,, S. C. Jr, Pollack,, C. V. Jr, Gibler, W. B., Ohman, E. M., for the CRUSADE Investigators, (2004). Utilization of Early Invasive Management Strategies for High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative. JAMA 292: 2096-2104 [Abstract] [Full Text]  
• Pedrini, M., Hartig, F., Pechlaner, C. (2004). Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome. JAMA 292: 1952-1952 [Full Text]  
• de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Brady, W. E., White, H. D., Fox, K. A.A., Palmisano, J., Ramsey, K. E., Bilheimer, D. W., Lewis, E. F., Pfeffer, M., Califf, R. M., Braunwald, E., for the A to Z Investigators, (2004). Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J 25: 1688-1694 [Abstract] [Full Text]  
• Wiggins, B. S., Spinler, S. (2004). Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. Journal of Pharmacy Practice 17: 347-369 [Abstract]  
• Ma, J. M, Jackevicius, C. A, Yeo, E. (2004). Anti-Xa Monitoring of Enoxaparin for Acute Coronary Syndromes in Patients with Renal Disease. The Annals of Pharmacotherapy 38: 1576-1581 [Abstract] [Full Text]  
• Harrington, R. A., Becker, R. C., Ezekowitz, M., Meade, T. W., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H. (2004). Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 513S-548S [Abstract] [Full Text]  
• Montalescot, G., Collet, J.P., Tanguy, M.L., Ankri, A., Payot, L., Dumaine, R., Choussat, R., Beygui, F., Gallois, V., Thomas, D. (2004). Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin. Circulation 110: 392-398 [Abstract] [Full Text]  
• SYNERGY Trial Investigators, (2004). Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy: Primary Results of the SYNERGY Randomized Trial. JAMA 292: 45-54 [Abstract] [Full Text]  
• Blazing, M. A., de Lemos, J. A., White, H. D., Fox, K. A. A., Verheugt, F. W. A., Ardissino, D., DiBattiste, P. M., Palmisano, J., Bilheimer, D. W., Snapinn, S. M., Ramsey, K. E., Gardner, L. H., Hasselblad, V., Pfeffer, M. A., Lewis, E. F., Braunwald, E., Califf, R. M., for the A to Z Investigators, (2004). Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin: A Randomized Controlled Trial. JAMA 292: 55-64 [Abstract] [Full Text]  
• Petersen, J. L., Mahaffey, K. W., Hasselblad, V., Antman, E. M., Cohen, M., Goodman, S. G., Langer, A., Blazing, M. A., Le-Moigne-Amrani, A., de Lemos, J. A., Nessel, C. C., Harrington, R. A., Ferguson, J. J., Braunwald, E., Califf, R. M. (2004). Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview. JAMA 292: 89-96 [Abstract] [Full Text]  
• Viles-Gonzalez, J. F, Fuster, V., Badimon, J. J (2004). Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J 25: 1197-1207 [Abstract] [Full Text]  
• Simoons, M. L., Bobbink, I. W. G., Boland, J., Gardien, M., Klootwijk, P., Lensing, A. W. A., Ruzyllo, W., Umans, V. A. W. M., Vahanian, A., Van De Werf, F., Zeymer, U., PENTUA Investigators, (2004). A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study. J Am Coll Cardiol 43: 2183-2190 [Abstract] [Full Text]  
• Aggarwal, A., Whitaker, D. A., Rimmer, J. M., Solomon, R. J., Gennari, F. J., Sobel, B. E., Schneider, D. J. (2004). Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. Nephrol Dial Transplant 19: 1559-1563 [Abstract] [Full Text]  
• Trichon, B. H, Roe, M. T (2004). Acute coronary syndromes and diabetes mellitus. Diabetes and Vascular Disease Research 1: 23-32 [Abstract]  
• Macie, C., Forbes, L., Foster, G. A., Douketis, J. D. (2004). Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome. Chest 125: 1616-1621 [Abstract] [Full Text]  
• Spyropoulos, A. C., Frost, F. J., Hurley, J. S., Roberts, M. (2004). Costs and Clinical Outcomes Associated With Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Bridging in Patients Receiving Long-term Oral Anticoagulant Therapy. Chest 125: 1642-1650 [Abstract] [Full Text]  
• Antman, E. M (2004). The re-emergence of anticoagulation in coronary disease. Eur Heart J Suppl 6: B2-B8 [Abstract] [Full Text]  
• Lev, E. I., Hasdai, D., Scapa, E., Tobar, A., Assali, A., Lahav, J., Battler, A., Badimon, J. J., Kornowski, R. (2004). Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: Effect on platelet function and thrombus formation. J Am Coll Cardiol 43: 966-971 [Abstract] [Full Text]  
• Stellbrink, C., Nixdorff, U., Hofmann, T., Lehmacher, W., Daniel, W. G., Hanrath, P., Geller, C., Mugge, A., Sehnert, W., Schmidt-Lucke, C., Schmidt-Lucke, J.-A., on Behalf of the ACE (Anticoagulation in Cardiover, (2004). Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Circulation 109: 997-1003 [Abstract] [Full Text]  
• Thorevska, N., Amoateng-Adjepong, Y., Sabahi, R., Schiopescu, I., Salloum, A., Muralidharan, V., Manthous, C. A. (2004). Anticoagulation in Hospitalized Patients With Renal Insufficiency: A Comparison of Bleeding Rates With Unfractionated Heparin vs Enoxaparin. Chest 125: 856-863 [Abstract] [Full Text]  
• Baker, C. S R (2004). Learning on the Web. Case 3: acute chest pain.. Heart 90: 112-112 [Full Text]  
• Bijsterveld, N. R., Peters, R. J. G., Murphy, S. A., Bernink, P. J. L. M., Tijssen, J. G. P., Cohen, M., TIMI 11B/ESSENCE Study Groups, (2003). Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave coronary events (ESSENCE) studies. J Am Coll Cardiol 42: 2083-2089 [Abstract] [Full Text]  
• Fareed, J., Ma, Q., Florian, M., Maddineni, J., Iqbal, O., Hoppensteadt, D. A., Bick, R. (2003). Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and Pharmacology. SEMIN CARDIOTHORAC VASC ANESTH 7: 357-377 [Abstract]  
• Medalion, B., Frenkel, G., Patachenko, P., Hauptman, E., Sasson, L., Schachner, A. (2003). Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 126: 1875-1879 [Abstract] [Full Text]  
• Braunwald, E. (2003). Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. Circulation 108: III-28-37 [Abstract] [Full Text]  
• Cohen, M., Gensini, G. F., Maritz, F., Gurfinkel, E. P., Huber, K., Timerman, A., Krzeminska-Pakula, M., Danchin, N., White, H. D., Santopinto, J., Bigonzi, F., Hecquet, C., Vittori, L., TETAMI Investigators, (2003). The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial. J Am Coll Cardiol 42: 1348-1356 [Abstract] [Full Text]  
• Leong, W., Hoppensteadt, D. A. (2003). Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations. CLIN APPL THROMB HEMOST 9: 293-297 [Abstract]  
• Dubois, C. L., Belmans, A., Granger, C. B., Armstrong, P. W., Wallentin, L., Fioretti, P. M., Lopez-Sendon, J. L., Verheugt, F. W., Meyer, J., Van de Werf, F., ASSENT-3 Investigators, (2003). Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol 42: 1178-1185 [Abstract] [Full Text]  
• Aronow, W. S. (2003). Review Article: Treatment of Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 58: M927-933 [Abstract] [Full Text]  
• Prasad, A., Mathew, V., Holmes, D. R Jr., Gersh, B. J (2003). Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials. Eur Heart J 24: 1544-1553 [Abstract] [Full Text]  
• Gunn, J, Taggart, D P (2003). Revascularisation for acute coronary syndromes: PCI or CABG?. Heart 89: 967-970 [Full Text]  
• Bijsterveld, N. R., Moons, A. H., Meijers, J. C. M., Levi, M., Buller, H. R., Peters, R. J. G. (2003). The impact on coagulation of an intravenous loading dose in addition to a subcutaneousregimen of low-molecular-weight heparinin the initial treatment of acute coronary syndromes. J Am Coll Cardiol 42: 424-427 [Abstract] [Full Text]  
• Kincaid, E. H., Monroe, M. L., Saliba, D. L., Kon, N. D., Byerly, W. G., Reichert, M. G. (2003). Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. Ann. Thorac. Surg. 76: 124-128 [Abstract] [Full Text]  
• Nutescu, E. A, Lewis, R. K, Finley, J. M, Schumock, G. T (2003). Hospital Guidelines for Use of Low-Molecular-Weight Heparins. The Annals of Pharmacotherapy 37: 1072-1081 [Abstract] [Full Text]  
• Crouch, M. A, Nappi, J. M, Cheang, K. I (2003). Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome. The Annals of Pharmacotherapy 37: 860-875 [Abstract] [Full Text]  
• Chow, S. L., Zammit, K., West, K., Dannenhoffer, M., Lopez-Candales, A. (2003). Correlation of Antifactor Xa Concentrations with Renal Function in Patients on Enoxaparin. J Clin Pharmacol 43: 586-590 [Abstract] [Full Text]  
• Wallentin, L., Bergstrand, L., Dellborg, M., Fellenius, C., Granger, C. B, Lindahl, B., Lins, L.-E., Nilsson, T., Pehrsson, K., Siegbahn, A., Swahn, E., for the ASSENT PLUS Investigators, (2003). Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction--the ASSENT Plus study. Eur Heart J 24: 897-908 [Abstract] [Full Text]  
• Janzon, M, Levin, L-A, Swahn, E (2003). Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial. Heart 89: 287-292 [Abstract] [Full Text]  
• Sarich, T. C., Wolzt, M., Eriksson, U. G., Mattsson, C., Schmidt, A., Elg, S., Andersson, M., Wollbratt, M., Fager, G., Gustafsson, D. (2003). Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 41: 557-564 [Abstract] [Full Text]  
• Monroe, V. S., Kerensky, R. A., Rivera, E., Smith, K. M., Pepine, C. J. (2003). Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. J Am Coll Cardiol 41: 23S-30S [Abstract] [Full Text]  
• Cohen, M. (2003). The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol 41: 55S-61S [Abstract] [Full Text]  
• Sabatine, M. S., Antman, E. M. (2003). The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 41: 89S-95S [Abstract] [Full Text]  
• McKay, R. G. (2003). "Ischemia-guided" versus "early invasive" strategies in the management of acute coronary syndrome/non-ST-segment elevation myocardial infarction: The interventionalist's perspective. J Am Coll Cardiol 41: 96S-102S [Abstract] [Full Text]  
• Nissen, S. E. (2003). Pathobiology, not angiography, should guide managementin acute coronary syndrome/non-ST-segment elevation myocardial infarction: The non-interventionist's perspective. J Am Coll Cardiol 41: 103S-112S [Abstract] [Full Text]  
• Topol, E. J. (2003). A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 41: 123S-129S [Abstract] [Full Text]